carbon monoxide has been researched along with Dyspnea in 41 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
Dyspnea: Difficult or labored breathing.
Excerpt | Relevance | Reference |
---|---|---|
" The following parameters were also evaluated: pulmonary function tests including diffusion capacity for carbon monoxide (Dlco), the modified Medical Research Council dyspnea score, COPD assessment test (CAT), and 6-min walk test (6MWT)." | 3.85 | Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation. ( Alcaide, AB; Bastarrika, G; Berto, J; Campo, A; Celli, BR; de-Torres, JP; Fernandez-Montero, A; Ocon, MD; Sanchez-Salcedo, P; Zulueta, JJ, 2017) |
" Women with breast cancer had lower lung diffusing capacity for carbon monoxide (DLCO), respiratory and limb muscle strength, and ventilatory thresholds during exercise compared with controls (all P < 0." | 3.83 | Respiratory Factors Contributing to Exercise Intolerance in Breast Cancer Survivors: A Case-Control Study. ( Dudgeon, DJ; Elbehairy, AF; Langer, D; Neder, JA; O'Donnell, DE; Webb, KA, 2016) |
" They had an unusual pattern of cardiopulmonary abnormalities with mild to moderate airway obstruction, severe hypoxemia, hypocapnia, and a very low diffusing capacity for carbon monoxide (p < 0." | 3.73 | Severe pulmonary hypertension and chronic obstructive pulmonary disease. ( Bugnet, AS; Chaouat, A; Ducoloné, A; Ehrhart, M; Enache, I; Kadaoui, N; Kessler, R; Schott, R; Weitzenblum, E, 2005) |
" Spirometry, plethysmography, carbon monoxide diffusing capacity, 6-minute walking distance, and dyspnea score were assessed preoperatively and at predetermined times after operation." | 3.73 | Lung-volume reduction surgery as an alternative or bridging procedure to lung transplantation. ( Bloch, KE; Boehler, A; Imfeld, S; Korom, S; Lardinois, D; Russi, EW; Speich, R; Tutic, M; Weder, W, 2006) |
"Respiratory dysfunction in Parkinson's disease (PD) is common and associated with increased hospital admission and mortality rates." | 3.01 | A systematic review and meta-analysis of respiratory dysfunction in Parkinson's disease. ( Blake, C; Lennon, O; McMahon, L, 2023) |
"No treatment-emergent serious adverse events were reported." | 2.84 | Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial. ( DiFede, D; Fishman, J; Glassberg, MK; Hare, JM; Khan, A; Lancaster, LH; LaRussa, VF; Mageto, YN; Mendizabal, A; Minkiewicz, J; Pujol, MV; Rosen, GD; Rubio, GA; Shafazand, S; Simonet, ES; Toonkel, RL, 2017) |
"Up to 60% of the mice showed dyspnea, airway obstruction and hypoxemia and died between days 7 and 12 post-infection." | 1.36 | VEGF promotes malaria-associated acute lung injury in mice. ( Ataíde, R; Campos, MG; Carapau, D; Costa-Silva, A; Dias, S; Epiphanio, S; Félix, N; Marinho, CR; Monteiro, CA; Mota, MM; Pamplona, A; Pena, AC, 2010) |
"The 14 patients without emphysema had interstitial lung disease, pulmonary vascular disease, and other isolated findings." | 1.34 | Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. ( Aduen, JF; Alvarez, F; Biewend, M; Jolles, HI; Keller, CA; Mobin, SI; Venegas, C; Zisman, DA, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 10 (24.39) | 18.7374 |
1990's | 2 (4.88) | 18.2507 |
2000's | 9 (21.95) | 29.6817 |
2010's | 13 (31.71) | 24.3611 |
2020's | 7 (17.07) | 2.80 |
Authors | Studies |
---|---|
Yeo, J | 1 |
Kim, JY | 1 |
Kim, MH | 1 |
Park, JW | 1 |
Park, JK | 1 |
Lee, EB | 1 |
MacIntyre, N | 1 |
Balasubramanian, A | 1 |
Kaminsky, D | 1 |
Matheson, AM | 1 |
McIntosh, MJ | 1 |
Kooner, HK | 1 |
Lee, J | 1 |
Desaigoudar, V | 1 |
Bier, E | 1 |
Driehuys, B | 1 |
Svenningsen, S | 1 |
Santyr, GE | 1 |
Kirby, M | 1 |
Albert, MS | 1 |
Shepelytskyi, Y | 1 |
Grynko, V | 1 |
Ouriadov, A | 1 |
Abdelrazek, M | 1 |
Dhaliwal, I | 1 |
Nicholson, JM | 1 |
Parraga, G | 1 |
Alves, MM | 1 |
Dressel, H | 1 |
Radtke, T | 1 |
Gülhan, PY | 1 |
Arbak, PM | 1 |
Annakkaya, AN | 1 |
Balbay, EG | 1 |
Balbay, ÖA | 1 |
McMahon, L | 1 |
Blake, C | 1 |
Lennon, O | 1 |
Ahn, J | 1 |
Yeghiaian-Alvandi, R | 1 |
Hegi-Johnson, F | 1 |
Browne, LH | 1 |
Graham, PH | 1 |
Chin, Y | 1 |
Gee, H | 1 |
Vinod, S | 1 |
Ludbrook, J | 1 |
Last, A | 1 |
Dwyer, P | 1 |
Ong, A | 1 |
Aherne, N | 1 |
Azzi, M | 1 |
Hau, E | 1 |
Natalini, JG | 1 |
Swigris, JJ | 1 |
Morisset, J | 1 |
Elicker, BM | 1 |
Jones, KD | 1 |
Fischer, A | 1 |
Collard, HR | 1 |
Lee, JS | 1 |
Garske, LA | 1 |
Kunarajah, K | 1 |
Zimmerman, PV | 1 |
Adams, L | 1 |
Stewart, IB | 1 |
Kaminsky, DA | 1 |
Jarzembowski, SC | 1 |
Nathan, SD | 1 |
Costabel, U | 1 |
Albera, C | 1 |
Behr, J | 1 |
Wuyts, WA | 1 |
Kirchgaessler, KU | 1 |
Stauffer, JL | 1 |
Morgenthien, E | 1 |
Chou, W | 1 |
Limb, SL | 1 |
Noble, PW | 1 |
Pezzuto, A | 1 |
Spoto, C | 1 |
Vincenzi, B | 1 |
Tonini, G | 1 |
Olukogbon, KL | 1 |
Thomas, P | 1 |
Colasanti, R | 1 |
Hope-Gill, B | 1 |
Williams, EM | 1 |
O'Donnell, DE | 1 |
Webb, KA | 1 |
Langer, D | 1 |
Elbehairy, AF | 1 |
Neder, JA | 1 |
Dudgeon, DJ | 1 |
Alcaide, AB | 1 |
Sanchez-Salcedo, P | 1 |
Bastarrika, G | 1 |
Campo, A | 1 |
Berto, J | 1 |
Ocon, MD | 1 |
Fernandez-Montero, A | 1 |
Celli, BR | 1 |
Zulueta, JJ | 1 |
de-Torres, JP | 1 |
Glassberg, MK | 1 |
Minkiewicz, J | 1 |
Toonkel, RL | 1 |
Simonet, ES | 1 |
Rubio, GA | 1 |
DiFede, D | 1 |
Shafazand, S | 1 |
Khan, A | 1 |
Pujol, MV | 1 |
LaRussa, VF | 1 |
Lancaster, LH | 1 |
Rosen, GD | 1 |
Fishman, J | 1 |
Mageto, YN | 1 |
Mendizabal, A | 1 |
Hare, JM | 1 |
Epiphanio, S | 1 |
Campos, MG | 1 |
Pamplona, A | 1 |
Carapau, D | 1 |
Pena, AC | 1 |
Ataíde, R | 1 |
Monteiro, CA | 1 |
Félix, N | 1 |
Costa-Silva, A | 1 |
Marinho, CR | 1 |
Dias, S | 1 |
Mota, MM | 1 |
Süyür, H | 1 |
Bayram, N | 1 |
Aydın, N | 1 |
Uyar, M | 1 |
Gündoğdu, N | 1 |
Elbek, O | 1 |
Gasior, N | 1 |
David, M | 1 |
Millet, V | 1 |
Reynaud-Gaubert, M | 1 |
Dubus, JC | 1 |
Lawson, K | 1 |
Maher, TM | 1 |
Hansell, DM | 1 |
Nicholson, AG | 1 |
KLEINFELD, M | 1 |
MESSITE, J | 1 |
SHAPIRO, J | 1 |
SWENCICKI, R | 1 |
KILBURN, KH | 1 |
Khanna, D | 1 |
Clements, PJ | 1 |
Furst, DE | 1 |
Chon, Y | 1 |
Elashoff, R | 1 |
Roth, MD | 1 |
Sterz, MG | 1 |
Chung, J | 1 |
FitzGerald, JD | 1 |
Seibold, JR | 1 |
Varga, J | 1 |
Theodore, A | 1 |
Wigley, FM | 1 |
Silver, RM | 1 |
Steen, VD | 1 |
Mayes, MD | 1 |
Connolly, MK | 1 |
Fessler, BJ | 1 |
Rothfield, NF | 1 |
Mubarak, K | 1 |
Molitor, J | 1 |
Tashkin, DP | 1 |
Chaouat, A | 1 |
Bugnet, AS | 1 |
Kadaoui, N | 1 |
Schott, R | 1 |
Enache, I | 1 |
Ducoloné, A | 1 |
Ehrhart, M | 1 |
Kessler, R | 1 |
Weitzenblum, E | 1 |
Snyder, EM | 1 |
Johnson, BD | 1 |
Beck, KC | 1 |
Tutic, M | 1 |
Lardinois, D | 1 |
Imfeld, S | 1 |
Korom, S | 1 |
Boehler, A | 1 |
Speich, R | 1 |
Bloch, KE | 1 |
Russi, EW | 1 |
Weder, W | 1 |
Aduen, JF | 1 |
Zisman, DA | 1 |
Mobin, SI | 1 |
Venegas, C | 1 |
Alvarez, F | 1 |
Biewend, M | 1 |
Jolles, HI | 1 |
Keller, CA | 1 |
Launay, D | 1 |
Mouthon, L | 1 |
Hachulla, E | 1 |
Pagnoux, C | 1 |
de Groote, P | 1 |
Remy-Jardin, M | 1 |
Matran, R | 1 |
Lambert, M | 1 |
Queyrel, V | 1 |
Morell-Dubois, S | 1 |
Guillevin, L | 1 |
Hatron, PY | 1 |
Schuller, A | 1 |
Cottin, V | 1 |
Hot, A | 1 |
Cordier, JF | 1 |
Courtney, R | 1 |
Cohen, M | 1 |
Hazelrigg, S | 1 |
Boley, T | 1 |
Henkle, J | 1 |
Lawyer, C | 1 |
Johnstone, D | 1 |
Naunheim, K | 1 |
Keller, C | 1 |
Keenan, R | 1 |
Landreneau, R | 1 |
Sciurba, F | 1 |
Feins, R | 1 |
Levy, P | 1 |
Magee, M | 1 |
Long, W | 1 |
Tate, RB | 1 |
Neuman, M | 1 |
Manfreda, J | 1 |
Becker, AB | 1 |
Anthonisen, NR | 1 |
Scano, G | 1 |
Filippelli, M | 1 |
Romagnoli, I | 1 |
Mancini, M | 1 |
Misuri, G | 1 |
Duranti, R | 1 |
Rosi, E | 1 |
Lough, J | 1 |
Baudouin, J | 1 |
Thevenot, C | 1 |
Dezile, G | 1 |
Lavandier, M | 1 |
Homasson, JP | 1 |
Roullier, A | 1 |
Rubin, G | 1 |
Baume, P | 1 |
Vandenberg, R | 1 |
Emirgil, C | 1 |
Sobol, BJ | 1 |
Heymann, B | 1 |
Shibutani, K | 1 |
Miller, GJ | 1 |
Hearn, CE | 1 |
Edwards, RH | 1 |
Bates, DV | 1 |
Bell, GM | 1 |
Burnham, CD | 1 |
Hazucha, M | 1 |
Mantha, J | 1 |
Pengelly, LD | 1 |
Silverman, F | 1 |
Renzetti, AD | 1 |
Kobayashi, T | 1 |
Bigler, A | 1 |
Mitchell, MN | 1 |
Petrilli, FL | 1 |
Agnese, G | 1 |
Kanitz, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Utility of Breath-holding Test for Assessment of Pulmonary Disease Severity in Patients With Systemic Sclerosis[NCT04484948] | 120 participants (Actual) | Interventional | 2020-08-12 | Completed | |||
Lung Structure-Function In SurVivors of Mild and SEvere COVID-19 Infection: 129Xe MRI and CT For Rapid Evaluations and NExt-wave Healthcare Planning[NCT04584671] | 100 participants (Anticipated) | Observational | 2021-01-01 | Active, not recruiting | |||
A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis[NCT00287729] | Phase 3 | 344 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)[NCT01366209] | Phase 3 | 555 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis[NCT00287716] | Phase 3 | 435 participants (Actual) | Interventional | 2006-07-14 | Completed | ||
Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap[NCT03263130] | 60 participants (Anticipated) | Observational [Patient Registry] | 2017-01-01 | Recruiting | |||
A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Idiopathic Pulmonary Fibrosis[NCT02013700] | Phase 1 | 9 participants (Actual) | Interventional | 2013-11-13 | Terminated (stopped due to Study completed) | ||
An Open Clinical Study to Explore the Safety, Tolerance and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)[NCT05468502] | Phase 1 | 18 participants (Anticipated) | Interventional | 2022-10-10 | Recruiting | ||
Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)[NCT00883129] | Phase 2 | 142 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
Chronisch Obstruktive Lungenerkrankung Und Pulmonale Hypertonie: Prävalenz Und Lebensqualität[NCT01423071] | 220 participants (Actual) | Observational | 2011-08-31 | Completed | |||
A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)[NCT01725256] | Phase 2 | 29 participants (Actual) | Interventional | 2012-11-30 | Terminated (stopped due to Terminated early dt to acquisition of Sponsor and change in corporate priorities) | ||
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension[NCT01725269] | Phase 2 | 17 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to Terminated early dt acquisition of Sponsor and change in corporate priorities) | ||
Dysfunctional Breathing: Multidimensional Characterisation and Assessment Tool[NCT03043469] | 141 participants (Anticipated) | Observational | 2020-08-08 | Not yet recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Mean Change in Percent Predicted Forced Vital Capacity (FVC) as measured from baseline to week 72. It is calculated as the simple difference between baseline Percent Predicted FVC measurements and week 72 Percent Predicted FVC measurements. (NCT00287729)
Timeframe: Baseline to week 72
Intervention | Change in Percent Predicted FVC (Mean) |
---|---|
Pirfenidone (2403 mg/d) | -9 |
Placebo | -10 |
The mean change from baseline to week 72 in Dyspnea score was measured by the University of San Diego Shortness of Breath Questionnaire (UCSD SOBQ). The SOBQ is used to assess shortness of breath with various activities of daily living (for example, brushing ones teeth or mowing the lawn). Patients rated the severity of their shortness of breath experienced on an average day during the past week on a 6 point scale (0 to 5),with 0= not at all breathless, 4= severely breathless and 5= Maximally or unable to do because of breathlessness. (NCT00287729)
Timeframe: Baseline to Week 72
Intervention | Change in Dyspnea Score (Mean) |
---|---|
Pirfenidone (2403 mg/d) | 11.9 |
Placebo | 13.9 |
The change from baseline to week 72 in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs. It is calculated as the simple difference between baseline DLco measurements and week 72 DLco measurements. (NCT00287729)
Timeframe: Baseline to Week 72
Intervention | Change in Percent Predicted DLco (Mean) |
---|---|
Pirfenidone (2403 mg/d) | -9.8 |
Placebo | -9.2 |
The change from Baseline to week 72 in distance walked during the 6-Minute Walk Test. This measure was calculated as the simple difference between baseline distanced walked over 6 minutes and week 72 distance walked over 6 minutes as measured in meters (m). (NCT00287729)
Timeframe: Baseline to Week 72
Intervention | Change in Distance Walked in Meters (Mean) |
---|---|
Pirfenidone (2403 mg/d) | -45 |
Placebo | -77 |
The change from baseline to week 72 in worst oxygen saturation during the 6-Minute Walk Test as measure by Pulse Oximetry (SpO2) Level. It is calculated as the simple difference between baseline SpO2 measurements and week 72 SpO2 measurements. (NCT00287729)
Timeframe: Baseline to Week 72
Intervention | Change,Worst Oxygen Saturation (Percent) (Mean) |
---|---|
Pirfenidone (2403 mg/d) | -1.9 |
Placebo | -1.3 |
Based on the change in baseline percent predicted FVC at week 72, patients were assigned to 1 of 5 categories: mild decline (<10% but >=0% decline), moderate decline (<20% but >=10% decline), severe decline (>=20% decline), mild improvement (>0% but <10% improvement), or moderate improvement (>=10% improvement). Those who died or had a lung transplant before Week 72 were included in the severe decline category. The results indicate the number of patients who experience Categorical Change in Percent Predicted Forced Vital Capacity. (NCT00287729)
Timeframe: Baseline to week 72
Intervention | Patients (Number) | ||||
---|---|---|---|---|---|
Decline >=20% or death or lung transplantation | Decline <20% but >= 10% | Decline <10% but > 0% | Improvement of >=0% but <10% | Improvement of >=10% | |
Pirfenidone (2403 mg/d) | 20 | 19 | 88 | 41 | 3 |
Placebo | 23 | 23 | 89 | 33 | 5 |
Progression is defined as the first occurrence of a 10% absolute decline from baseline in percent predicted Forced Vital Capacity, a 15% absolute decline from baseline in percent predicted hemoglobin(Hgb)-corrected carbon monoxide diffusing capacity (DLco), or, death. (NCT00287729)
Timeframe: Baseline to Week 72
Intervention | Number of Patients with Progression (Number) | |||
---|---|---|---|---|
Death or Disease Progression | Decline in percent predicted FVC >=10% | Decline in percent predicted DLco >=15% | Death Before Disease Progression | |
Pirfenidone (2403 mg/d) | 54 | 31 | 10 | 13 |
Placebo | 60 | 41 | 9 | 10 |
"Worsening of IPF was defined by the occurrence of any of the following events:~Acute IPF exacerbation, IPF-related death, Lung transplantation, or Respiratory hospitalization." (NCT00287729)
Timeframe: Time to acute IPF exacerbation, IPF-related death, lung transplant or respiratory hospitalization, whichever comes first.
Intervention | Number of Patients Who Worsened (Number) | |||||
---|---|---|---|---|---|---|
Woresening IPF | Acute IPF exacerbation | IPF-related death | Lung transplantation | Respiratory hospitalization | Patients Censored | |
Pirfenidone (2403 mg/d) | 24 | 2 | 3 | 2 | 17 | 146 |
Placebo | 32 | 1 | 6 | 2 | 23 | 141 |
(NCT01366209)
Timeframe: 52 weeks
Intervention | percentage of patients (Number) | |
---|---|---|
Decline or >=10% or Death | No Decline (Change >0%) | |
Active Arm | 16.5 | 22.7 |
Placebo Arm | 31.8 | 9.7 |
Mean Change in Percent Predicted Forced Vital Capacity (FVC) as measured from baseline to week 72. (NCT00287716)
Timeframe: From baseline up to 72 weeks
Intervention | Change in Percent Predicted FVC (Mean) |
---|---|
Pirfenidone 2403 mg/Day | -8.0 |
Pirfenidone 1197 mg/Day | -10.0 |
Placebo | -12.4 |
The mean change from baseline to week 72 in Dyspnea score was measured by the University of San Diego Shortness of Breath Questionnaire (UCSD SOBQ). The SOBQ is used to assess shortness of breath with various activities of daily living (for example, brushing ones teeth or mowing the lawn). Patients rated the severity of their shortness of breath experienced on an average day during the past week on a 6 point scale (0 to 5), with 0 = not at all breathless, 4= severely breathless and 5 = Maximally or unable to do because of breathlessness. (NCT00287716)
Timeframe: Baseline to Week 72
Intervention | Change in Dyspnea Score (Mean) |
---|---|
Pirfenidone 2403 mg/Day | 12 |
Pirfenidone 1197 mg/Day | 14 |
Placebo | 15 |
(NCT00287716)
Timeframe: Baseline to Week 72
Intervention | Change in Percent Predicted DLco (Mean) |
---|---|
Pirfenidone 2403 mg/Day | -8 |
Pirfenidone 1197 mg/Day | -9 |
Placebo | -10 |
The change from Baseline to week 72 in distance walked during the 6-Minute Walk Test as measured in meters (m). (NCT00287716)
Timeframe: Baseline to Week 72
Intervention | Change in Distance Walked in Meters (Mean) |
---|---|
Pirfenidone 2403 mg/Day | -60 |
Pirfenidone 1197 mg/Day | -76 |
Placebo | -77 |
The change from baseline to week 72 in worst oxygen saturation during the 6-Minute Walk Test as measure by Pulse Oximetry (SpO2) Level is calculated as the simple difference between baseline SpO2 measurements and week 72 SpO2 measurements. (NCT00287716)
Timeframe: Baseline to Week 72
Intervention | Change,Worst Oxygen Saturation (Percent) (Mean) |
---|---|
Pirfenidone 2403 mg/Day | -2 |
Pirfenidone 1197 mg/Day | -1 |
Placebo | -2 |
"Worsening of IPF was defined by the occurrence of any of the following events:~Acute IPF exacerbation, IPF-related death, Lung transplantation, or Respiratory hospitalization." (NCT00287716)
Timeframe: Time to acute IPF exacerbation, IPF-related death, lung transplant or respiratory hospitalization, whichever comes first.
Intervention | Number of Patients Who Worsened (Number) |
---|---|
Pirfenidone 2403 mg/Day | 26 |
Pirfenidone 1197 mg/Day | 10 |
Placebo | 30 |
Based on the change in baseline percent predicted FVC at week 72, patients were assigned to 1 of 5 categories: mild decline (<10% but >=0% decline), moderate decline (<20% but >=10% decline), severe decline (>=20% decline), mild improvement (>0% but <10% improvement), or moderate improvement (>=10% improvement). Those who died or had a lung transplant before Week 72 were included in the severe decline category. The results indicate the number of patients who experienced a Categorical Change in Percent Predicted Forced Vital Capacity. (NCT00287716)
Timeframe: baseline up to 72 weeks
Intervention | Patients (Number) | ||||
---|---|---|---|---|---|
Severe decline of >=20%, death, or lung transplant | Moderate decline of <20% but >=10% | Mild decline of <10% but >=0% | Mild improvement of >0% but <10% | Moderate improvement of >=10% | |
Pirfenidone 1197 mg/Day | 9 | 14 | 51 | 12 | 1 |
Pirfenidone 2403 mg/Day | 14 | 21 | 97 | 40 | 2 |
Placebo | 27 | 33 | 90 | 24 | 0 |
Progression is defined as the first occurrence of a 10% absolute decline from baseline in percent predicted Forced Vital Capacity, a 15% absolute decline from baseline in percent predicted hemoglobin(Hgb)-corrected carbon monoxide diffusing capacity (DLco), or, death. (NCT00287716)
Timeframe: Baseline to Week 72
Intervention | Number of Patients with Progression (Number) | |||
---|---|---|---|---|
Death or Disease Progression | Decline in Percent Predicted FVC >=10% | Decline in Percent Predicted DLco >=15% | Death Before Disease Progression | |
Pirfenidone 1197 mg/Day | 28 | 16 | 5 | 7 |
Pirfenidone 2403 mg/Day | 45 | 28 | 9 | 8 |
Placebo | 62 | 39 | 9 | 14 |
Imaging of the whole lung (WL) is performed using a volumetric high resolution computerized tomography (HRCT) scan, which is then analyzed using a computer algorithm to determine the percentage of overall pixels exhibiting features characteristic for quantitative lung fibrosis (QLF). Higher percentages for QLF-WL therefore represent greater involvement by lung fibrosis. (NCT00883129)
Timeframe: Measured at baseline and Month 24
Intervention | % of lung exhibiting QLF (Mean) | |
---|---|---|
Baseline | Month 24 | |
Cyclophosphamide Arm | 8.91 | 8.48 |
Mycophenolate Arm | 8.25 | 7.99 |
The primary outcome is the course over time from baseline to 24 months for the FVC %-predicted. The FVC %-predicted represents the adjusted volume of air (adjusted as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity) that can be forcibly exhaled from the lungs after taking the deepest breath possible. The FVC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of lung involvement and disease severity. (NCT00883129)
Timeframe: Measured at study Baseline and Months 3, 6, 12, 15, 18, 21, and 24
Intervention | FVC %-pred (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
Cyclophosphamide Arm | 66.52 | 67.03 | 67.86 | 69.42 | 69.86 | 71.94 | 72.57 | 72.55 | 70.15 |
Mycophenolate Arm | 66.52 | 66.22 | 68.02 | 68.11 | 68.43 | 69.84 | 70.57 | 70.87 | 69.65 |
The HAQ-DI asks questions related to 8 activity domains (dressing, arising, eating, walking, hygiene, reach, grip, and common daily activities) with the patient's capacity to carry out each activity scored from 0 to 3. Scores across all domains are averaged and a higher score represents greater disability. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 9, 12, 15, 18, 21, and 24
Intervention | HAQ-DI Total Score (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
Cyclophosphamide Arm | 0.74 | 0.64 | 0.58 | 0.65 | 0.56 | 0.62 | 0.55 | 0.48 | 0.57 |
Mycophenolate Arm | 0.71 | 0.83 | 0.75 | 0.66 | 0.64 | 0.58 | 0.55 | 0.65 | 0.62 |
The DLCO is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLCO %-predicted represents the DLCO expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The DLCO %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 12, 15, 18, 21, and 24
Intervention | DLCO %-pred (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
Cyclophosphamide Arm | 54.05 | 51.92 | 50.87 | 51.55 | 53.12 | 53.62 | 55.9 | 54.26 | 52.90 |
Mycophenolate Arm | 53.99 | 53.38 | 54.86 | 54.13 | 55.32 | 57.77 | 56.62 | 55.47 | 55.31 |
Skin thickness is quantified using the modified Rodnan measurement method (mRSS), with a scale that ranges from 0 (no skin involvement) to a maximum of 51. The reported skin score is determined by a clinical assessment of skin thickness, which is performed by a trained reader, and represents the sum of individual assessments that are made in each of 17 body areas. Each area is given a score in the range of 0-3 (0 = normal; 1= mild thickness; 2 = moderate; 3 = severe thickness). A higher score represents more severe skin involvement. (NCT00883129)
Timeframe: Measured at baseline and Months 3, 6, 9, 12, 15, 18, 21, and 24
Intervention | mRSS score (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
Cyclophosphamide Arm | 14.04 | 12.85 | 11.95 | 10.61 | 9.47 | 9.80 | 9.87 | 8.50 | 7.87 |
Mycophenolate Arm | 15.32 | 16.03 | 14.37 | 14.33 | 12.45 | 12.43 | 11.98 | 11.22 | 11.40 |
The number of participants who remained in the study at the listed time points are reported (NCT00883129)
Timeframe: Continuous assessment from randomization to 24 months
Intervention | Participants (Count of Participants) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
Cyclophosphamide Arm | 73 | 64 | 56 | 51 | 46 | 44 | 42 | 39 | 38 |
Mycophenolate Arm | 69 | 66 | 58 | 55 | 52 | 52 | 49 | 49 | 49 |
The TLC represents the total volume of air within the lung after taking the deepest breath possible and the TLC %-predicted represents the TLC expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The TLC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 6, 12, 18, and 24
Intervention | TLC %-pred (Mean) | ||||
---|---|---|---|---|---|
Baseline | Month 6 | Month 12 | Month 18 | Month 24 | |
Cyclophosphamide Arm | 65.49 | 67.39 | 68.25 | 69.63 | 66.97 |
Mycophenolate Arm | 66.16 | 67.84 | 67.31 | 68.50 | 68.24 |
(NCT00883129)
Timeframe: Measured throughout the 2-year study
Intervention | Participants (Count of Participants) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Leukopenia (<2.5x10^3 WBC/microliter) | Neutropenia (<1.0x10^3 neutrophils/microliter) | Anemia (Hgb <10 g/dl) | Thrombocytopenia (<100x10^3 platelets/microliter) | Hematuria (>10 RBC/high power field) | Pneumonia | SAE-Total | SAE-related to treatment | Deaths | |
Cyclophosphamide Arm | 30 | 7 | 13 | 4 | 2 | 4 | 22 | 7 | 11 |
Mycophenolate Arm | 4 | 3 | 8 | 0 | 3 | 5 | 27 | 3 | 5 |
Change in breathlessness was assessed using the Transitional Dyspnea Index, which compares current symptoms to those at baseline. Total score ranges from - 9 to + 9. The lower the score, the more deterioration in severity of dyspnea. (NCT00883129)
Timeframe: Measured at Months 6, 12, 18, and 24
Intervention | Transitional Dyspnea Index Score (Mean) | |||
---|---|---|---|---|
Month 6 | Month 12 | Month 18 | Month 24 | |
Cyclophosphamide Arm | 0.31 | 1.23 | 1.78 | 2.09 |
Mycophenolate Arm | 0.74 | 1.17 | 0.91 | 1.86 |
2 reviews available for carbon monoxide and Dyspnea
Article | Year |
---|---|
A systematic review and meta-analysis of respiratory dysfunction in Parkinson's disease.
Topics: Carbon Monoxide; Case-Control Studies; Cough; Disease Progression; Dyspnea; Humans; Lung Volume Meas | 2023 |
[Adult respiratory sequelae of premature birth].
Topics: Adolescent; Adult; Bronchial Hyperreactivity; Bronchopulmonary Dysplasia; Carbon Monoxide; Disease P | 2011 |
4 trials available for carbon monoxide and Dyspnea
Article | Year |
---|---|
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud | 2019 |
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud | 2019 |
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud | 2019 |
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud | 2019 |
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud | 2019 |
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud | 2019 |
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud | 2019 |
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud | 2019 |
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Stud | 2019 |
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
Topics: Administration, Intravenous; Aged; Carbon Monoxide; Disease Progression; Dyspnea; Female; Hospitaliz | 2017 |
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
Topics: Administration, Intravenous; Aged; Carbon Monoxide; Disease Progression; Dyspnea; Female; Hospitaliz | 2017 |
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
Topics: Administration, Intravenous; Aged; Carbon Monoxide; Disease Progression; Dyspnea; Female; Hospitaliz | 2017 |
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
Topics: Administration, Intravenous; Aged; Carbon Monoxide; Disease Progression; Dyspnea; Female; Hospitaliz | 2017 |
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Topics: Carbon Monoxide; Double-Blind Method; Dyspnea; Female; Health Status; Humans; Lung Diseases; Male; M | 2005 |
An open-circuit method for determining lung diffusing capacity during exercise: comparison to rebreathe.
Topics: Adult; Carbon Monoxide; Cardiac Output; Dyspnea; Exercise; Female; Humans; Male; Middle Aged; Pulmon | 2005 |
35 other studies available for carbon monoxide and Dyspnea
Article | Year |
---|---|
Utility of the breath-holding test in patients with systemic sclerosis.
Topics: Biomarkers; Carbon Monoxide; Dyspnea; Humans; Reproducibility of Results; Scleroderma, Systemic; Str | 2022 |
Diffusing Capacity of the Lungs for Carbon Monoxide Test.
Topics: Breath Holding; Breath Tests; Carbon Monoxide; Dyspnea; Forced Expiratory Volume; Hemoglobin A; Huma | 2022 |
Persistent
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbon Monoxide; COVID-19; Dyspnea; Female; Humans; Lung | 2022 |
Test-retest reliability of lung diffusing capacity for nitric oxide during light to moderate intensity cycling exercise.
Topics: Adult; Aged; Carbon Monoxide; Dyspnea; Humans; Hyperplasia; Lung; Middle Aged; Nitric Oxide; Pulmona | 2022 |
An assessment of post-COVID-19 infection pulmonary functions in healthcare professionals.
Topics: Adult; Carbon Monoxide; COVID-19; Delivery of Health Care; Dyspnea; Female; Humans; Lung; Male; Midd | 2022 |
SABR for Early Non-Small Cell Lung Cancer: Changes in Pulmonary Function, Dyspnea, and Quality of Life.
Topics: Carbon Monoxide; Carcinoma, Non-Small-Cell Lung; Dyspnea; Humans; Lung; Lung Neoplasms; Prospective | 2023 |
Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.
Topics: Aged; Arthritis, Rheumatoid; Carbon Monoxide; Cohort Studies; Dyspnea; Female; Forced Expiratory Vol | 2017 |
In patients with unilateral pleural effusion, restricted lung inflation is the principal predictor of increased dyspnoea.
Topics: Carbon Monoxide; Chromatography, Thin Layer; Diaphragm; Dyspnea; Female; Humans; Lung; Male; Pleura; | 2018 |
Influence of Mouth Pressure on Measurement of Diffusing Capacity in the Clinical Pulmonary Function Laboratory.
Topics: Adult; Aged; Asthma; Breath Holding; Carbon Monoxide; Dyspnea; Female; Forced Expiratory Volume; Hum | 2019 |
Short-term effectiveness of smoking-cessation treatment on respiratory function and CEA level.
Topics: Benzazepines; Carbon Monoxide; Carboxyhemoglobin; Carcinoembryonic Antigen; Combined Modality Therap | 2013 |
Breathing pattern and breathlessness in idiopathic pulmonary fibrosis: An observational study.
Topics: Aged; Aged, 80 and over; Carbon Monoxide; Case-Control Studies; Dyspnea; Exhalation; Female; Humans; | 2016 |
Respiratory Factors Contributing to Exercise Intolerance in Breast Cancer Survivors: A Case-Control Study.
Topics: Breast Neoplasms; Cancer Survivors; Carbon Monoxide; Case-Control Studies; Dyspnea; Exercise Test; E | 2016 |
Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation.
Topics: Activities of Daily Living; Aged; Carbon Monoxide; Case-Control Studies; Cross-Sectional Studies; Dy | 2017 |
VEGF promotes malaria-associated acute lung injury in mice.
Topics: Acute Lung Injury; Airway Obstruction; Animals; Anti-Inflammatory Agents; Carbon Monoxide; Disease M | 2010 |
[Pulmonary manifestations of polyvinyl chloride exposure].
Topics: Adult; Carbon Monoxide; Cough; Diffusion; Dust; Dyspnea; Female; Humans; Incidence; Lung Diseases; M | 2011 |
Successful treatment of progressive diffuse PEComatosis.
Topics: Adult; Biopsy; Carbon Monoxide; Cell Proliferation; Dyspnea; Female; Genotype; Humans; Lung; Lung Di | 2012 |
EFFECT OF TALE DUST INHALATION ON LUNG FUNCTION.
Topics: Bradycardia; Carbon Monoxide; Cardiomegaly; Cough; Dust; Dyspnea; Electrocardiography; Oximetry; Pne | 1965 |
TACHYPNEA AND HYPERPNEA; SIGNS OF COMPENSATORY VENTILATION.
Topics: Acid-Base Equilibrium; Bicarbonates; Blood Gas Analysis; Carbon Dioxide; Carbon Monoxide; Dyspnea; H | 1965 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Lung-volume reduction surgery as an alternative or bridging procedure to lung transplantation.
Topics: Adult; Aged; Carbon Monoxide; Dyspnea; Exercise Test; Female; Follow-Up Studies; Forced Expiratory V | 2006 |
Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Dyspnea; Echocardiography; Female; Humans; Lung Dis | 2007 |
Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
Topics: Adult; Carbon Monoxide; Comorbidity; Dyspnea; Female; Humans; Hypertension, Pulmonary; Lung Diseases | 2007 |
Finger clubbing and altered carbon monoxide transfer capacity in cannabis smokers.
Topics: Adult; Blood Gas Analysis; Carbon Monoxide; Dyspnea; Follow-Up Studies; Humans; Male; Marijuana Smok | 2008 |
Investigating the claims of Konstantin Buteyko, M.D., Ph.D.: the relationship of breath holding time to end tidal CO2 and other proposed measures of dysfunctional breathing.
Topics: Adult; Breath Tests; Breathing Exercises; Carbon Monoxide; Dyspnea; Female; Humans; Male; Reference | 2008 |
Thoracoscopic laser bullectomy: a prospective study with three-month results.
Topics: Acid-Base Imbalance; Adult; Aged; Blister; Carbon Dioxide; Carbon Monoxide; Dyspnea; Echocardiograph | 1996 |
Respiratory symptoms in a susceptible population due to burning of agricultural residue.
Topics: Adult; Agriculture; Air Pollutants; Air Pollution; Airway Obstruction; Asthma; Bronchial Hyperreacti | 1998 |
Hypoxic and hypercapnic breathlessness in patients with type I diabetes mellitus.
Topics: Adult; Breath Tests; Carbon Dioxide; Carbon Monoxide; Diabetes Mellitus, Type 1; Dyspnea; Elasticity | 2000 |
Cardiomyopathy produced by cigarette smoke. Ultrastructural observations in guinea pigs.
Topics: Animals; Carbon Monoxide; Cardiomegaly; Cyanosis; Dyspnea; Guinea Pigs; Heart Diseases; Male; Mitoch | 1978 |
[Pulmonary fibrosis by hard metals. Functional and immunological study of 4 cases].
Topics: Adult; Aged; Carbon; Carbon Monoxide; Cobalt; DNA; Dyspnea; Humans; Immunoglobulin E; Immunologic De | 1974 |
Azathioprin nd acute restrictive lung disese.
Topics: Acute Disease; Adult; Azathioprine; Carbon Monoxide; Colitis, Ulcerative; Cough; Dyspnea; Humans; Lu | 1972 |
Pulmonary function in alcoholics.
Topics: Adult; Alcoholism; Bronchitis; Carbon Monoxide; Disease Susceptibility; Dyspnea; Ethanol; Female; Hu | 1974 |
Pulmonary function at rest and during exercise following bagassosis.
Topics: Blood Volume; Capillaries; Carbon Monoxide; Cromolyn Sodium; Dyspnea; Fungi; Humans; Hypercapnia; Lu | 1971 |
Short-term effects of ozone on the lung.
Topics: Adult; Airway Resistance; Analysis of Variance; Carbon Monoxide; Cough; Dyspnea; Humans; Lung; Lung | 1972 |
Regional ventilation and perfusion in silicosis and in the alveolar-capillary block syndrome.
Topics: Adult; Aged; Arthritis, Rheumatoid; Body Surface Area; Bronchitis; Capillaries; Carbon Dioxide; Carb | 1970 |
Epidemiologic studies of air pollution effects in Genoa, Italy.
Topics: Air Pollution; Benzopyrenes; Bronchitis; Carbon Monoxide; Cough; Dyspnea; Environmental Health; Fema | 1966 |